AKT1 and glioblastoma: Additionally, shikonin treatment was found to reduce the viability, migration and invasion of the GBM cell lines U87 and U251 and also to decrease the expression of MMP-2 and MMP-9, conceivably through the inhibition of PI3K/Akt signaling [279].